GILD - Gilead Sciences, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
67.10
+0.74 (+1.12%)
At close: 4:00PM EDT

67.10 0.00 (0.00%)
After hours: 4:48PM EDT

Stock chart is not supported by your current browser
Previous Close66.36
Open66.47
Bid67.08 x 2200
Ask67.09 x 3100
Day's Range66.07 - 67.45
52 Week Range60.32 - 79.61
Volume3,918,960
Avg. Volume6,662,188
Market Cap85.321B
Beta (3Y Monthly)1.14
PE Ratio (TTM)14.81
EPS (TTM)4.53
Earnings DateJul 23, 2019 - Jul 29, 2019
Forward Dividend & Yield2.52 (3.87%)
Ex-Dividend Date2019-06-13
1y Target Est79.81
Trade prices are not sourced from all markets
  • AstraZeneca Gives Detailed Data From Calquence Leukemia Study
    Zacks9 hours ago

    AstraZeneca Gives Detailed Data From Calquence Leukemia Study

    AstraZeneca's (AZN) Calquence monotherapy prolongs progression-free survival significantly in relapsed or refractory CLL patients compared to Roche's Rituxan.

  • Better Buy: Aurora Cannabis vs. Gilead Sciences
    Motley Foolyesterday

    Better Buy: Aurora Cannabis vs. Gilead Sciences

    Between this unlikely pair, which stock is the better pick for long-term investors?

  • Markit2 days ago

    See what the IHS Markit Score report has to say about Gilead Sciences Inc.

    Gilead Sciences Inc NASDAQ/NGS:GILDView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for GILD with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting GILD. Money flowETF/Index ownership | NegativeETF activity is negative but appears to be improving. Over the last one-month, outflows of investor capital in ETFs holding GILD totaled $2.03 billion. However, outflows appear to be slowing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • GILD vs. ILMN: Which Stock Is the Better Value Option?
    Zacks3 days ago

    GILD vs. ILMN: Which Stock Is the Better Value Option?

    GILD vs. ILMN: Which Stock Is the Better Value Option?

  • 3 Top Dividend Stocks to Buy in June
    Motley Fool3 days ago

    3 Top Dividend Stocks to Buy in June

    Here's why it could be the perfect time to add these income stocks to your portfolio.

  • Amgen, Biogen, Gilead and Novo Nordisk have ‘very high’ capacity for M&A, says Moody’s
    MarketWatch4 days ago

    Amgen, Biogen, Gilead and Novo Nordisk have ‘very high’ capacity for M&A, says Moody’s

    Amgen Inc., Biogen Inc., Gilead Inc. and Novo Nordisk A/S all have “very high” capacity for M&A activity, Moody’s Investors Service said in a report published Thursday.

  • GuruFocus.com4 days ago

    5 Companies Raising Earnings

    Gilead Sciences on the list

  • Galapagos Ends Enrollment in Osteoarthritis Study Before Time
    Zacks5 days ago

    Galapagos Ends Enrollment in Osteoarthritis Study Before Time

    Galapagos (GLPG) closes enrollment in the phase II study on GLPG1972/S201086 for the treatment of patients with osteoarthritis prior to the stipulated date.

  • CymaBay Down on Dismal Interim Data From Mid-Stage NASH Study
    Zacks5 days ago

    CymaBay Down on Dismal Interim Data From Mid-Stage NASH Study

    CymaBay (CBAY) plummets as a phase IIb study on lead candidate, seladelpar, fails to show meaningful reductions in liver fat.

  • Is Gilead Sciences (GILD) Outperforming Other Medical Stocks This Year?
    Zacks5 days ago

    Is Gilead Sciences (GILD) Outperforming Other Medical Stocks This Year?

    Is (GILD) Outperforming Other Medical Stocks This Year?

  • MarketWatch6 days ago

    CymaBay Therapeutics stock down 43% after NASH trial data disappoint investors

    Shares of CymaBay Therapeutics Inc. plummeted 43% in premarket trade Tuesday after the biotech said data from an ongoing Phase 2 trial showed patients with nonalcoholic steatohepatitis (NASH) who were treated with investigational drug seladelpar did not show significant reductions in liver fat when compared with those on a placebo. However, treatment with seladelpar did result in a reduction in biomarkers associated with liver injury, the company said. "While the reductions in liver fat were minimal, we remain encouraged by the significant improvements in biochemical markers of liver injury that we observed at week 12," said Pol Boudes, CymaBay's chief medical officer. "The 52-week liver biopsy data will allow us to understand whether the improvement in liver injury markers will translate into histological improvement. The observed improvement in markers of liver injury are consistent with the observed effects of seladelpar in PBC and further support the potential for seladelpar to improve liver health." In NASH, fat builds up in the liver, triggering inflammation and cell injury that can lead to serious complications like cirrhosis, or liver scarring. There have been several trial updates in the NASH space so far this year from companies like Gilead Sciences Inc. and Intercept Pharmaceuticals Inc. , but they have not been promising, according to Jefferies health desk trader Jared Holz. "Investors have not been impressed with current data," he wrote in a note to clients Tuesday morning. Shares of CymaBay Therapeutics Inc. have gained 41% in the year to date through Monday, while the S&P 500 has gained 15%.

  • CNW Group7 days ago

    GT Biopharma Company Update

    GT Biopharma Company Update

  • Here's How We Evaluate Gilead Sciences, Inc.'s (NASDAQ:GILD) Dividend
    Simply Wall St.8 days ago

    Here's How We Evaluate Gilead Sciences, Inc.'s (NASDAQ:GILD) Dividend

    Dividend paying stocks like Gilead Sciences, Inc. (NASDAQ:GILD) tend to be popular with investors, and for good reason...

  • Is Gilead Sciences, Inc. (GILD) A Good Stock To Buy?
    Insider Monkey11 days ago

    Is Gilead Sciences, Inc. (GILD) A Good Stock To Buy?

    Hedge fund managers like David Einhorn, Bill Ackman, or Carl Icahn became billionaires through reaping large profits for their investors, which is why piggybacking their stock picks may provide us with significant returns as well. Many hedge funds, like Paul Singer’s Elliott Management, are pretty secretive, but we can still get some insights by analyzing […]

  • The Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, Gilead Sciences, Repligen, Illumina and Bio-Techne
    Zacks12 days ago

    The Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, Gilead Sciences, Repligen, Illumina and Bio-Techne

    The Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, Gilead Sciences, Repligen, Illumina and Bio-Techne

  • MoneyShow12 days ago

    Gerlach Sees Growth at Gilead

    Drug development is an uncertain enterprise. The rewards can be great, but failure is the most typical outcome, cautions growth stock expert Doug Gerlach, editor of Investor Advisory Service.

  • Gilead Stock Is Among The Biggest Biotech Stocks — But Should You Buy It?
    Investor's Business Daily13 days ago

    Gilead Stock Is Among The Biggest Biotech Stocks — But Should You Buy It?

    Gilead is one of the biggest biotech companies. But recent news and earnings have been mixed. So, is Gilead stock a buy right now? Read on for a full analysis.

  • 5 Biotech Stocks to Buy Right Now
    Zacks13 days ago

    5 Biotech Stocks to Buy Right Now

    here are a few stocks that have outperformed their peers and are expected to have continued growth throughout the next couple of years. All the stocks in this list are a Zacks Rank 2 (Buy) or better.

  • 3 Cancer Stocks Given a Lift by Amgen
    Motley Fool13 days ago

    3 Cancer Stocks Given a Lift by Amgen

    Success with an experimental new oncology treatment that scratches a 35-year itch is good news for more than one biotech stock.

  • Reuters14 days ago

    US STOCKS-Nasdaq confirms correction as Facebook, Alphabet, Amazon drag

    The Nasdaq tumbled 1.6% on Monday, confirming a correction as it was dragged down by Alphabet, Facebook and Amazon.com on fears the companies are the targets of U.S. government antitrust regulators. While the sell-off in the internet heavyweights was the biggest drag on the Nasdaq, the index has been falling steadily since its May 3 record closing high as investors worried about slowing global growth amid an escalating U.S.-China trade war. The S&P 500 had a volatile session and ended the day down 0.3 percent, but the Dow Jones Industrial Average ended the session virtually unchanged.

  • Health Care Digest: Why California biotech thrives, small company looks to crash NASH bash, meeting up at BIO
    American City Business Journals14 days ago

    Health Care Digest: Why California biotech thrives, small company looks to crash NASH bash, meeting up at BIO

    Our latest Health Care Digest is taking names and targeting the latest in biotech and health care news.

  • Gilead Presents Data on CAR T Cell Therapy Candidate at ASCO
    Zacks14 days ago

    Gilead Presents Data on CAR T Cell Therapy Candidate at ASCO

    Gilead (GILD) presents data from a phase I study on experimental CAR T cell therapy, KTE-X19, at ASCO and announces collaboration with Humanigen.

  • Kite Announces New Yescarta® Data From ZUMA-1
    Business Wire14 days ago

    Kite Announces New Yescarta® Data From ZUMA-1

    -- Sub-Population Analysis Demonstrates High Rates of Durable Response and Overall Survival Regardless of Age at Two Years Post-Treatment --